Drug Type Prophylactic vaccine, Dendritic cell vaccine |
Synonyms Acute myeloid leukaemia vaccine, Leukemic dendritic cell vaccine, Vididencel + [3] |
Target- |
Action stimulants |
Mechanism Immunostimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationFast Track (United States), Orphan Drug (United States), Orphan Drug (European Union) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute Myeloid Leukemia | Phase 2 | Australia | 14 Jun 2024 | |
Relapsing acute myeloid leukemia | Phase 2 | Finland | 15 Oct 2018 | |
Relapsing acute myeloid leukemia | Phase 2 | Germany | 15 Oct 2018 | |
Relapsing acute myeloid leukemia | Phase 2 | Netherlands | 15 Oct 2018 | |
Relapsing acute myeloid leukemia | Phase 2 | Norway | 15 Oct 2018 | |
Relapsing acute myeloid leukemia | Phase 2 | Sweden | 15 Oct 2018 | |
Residual Neoplasm | Phase 2 | Finland | 15 Oct 2018 | |
Residual Neoplasm | Phase 2 | Germany | 15 Oct 2018 | |
Residual Neoplasm | Phase 2 | Netherlands | 15 Oct 2018 | |
Residual Neoplasm | Phase 2 | Norway | 15 Oct 2018 |
Phase 2 | - | kzxvsijozw(lyguxunetu) = qpldiyawgj eysrqipzom (wfesowmkvu ) | Positive | 16 May 2025 | |||
Phase 2 | Acute Myeloid Leukemia NPM1 mutation | NPM1 wild type | 20 | (NPM1 mutated AML patients) | ovtpotibtk(qnycnzwizc) = vmlvczrphj dytxldcqrh (uarsivydlj ) View more | Positive | 14 May 2025 | |
(NPM1 wild type AML patients) | ovtpotibtk(qnycnzwizc) = cwtqjzaejj dytxldcqrh (uarsivydlj ) View more | ||||||
Phase 1 | 17 | zptcoyzade(ghiauerzyx) = kgxsvntwsq igjcsnxcvx (pqmmkkmdjp ) View more | Positive | 18 Dec 2024 | |||
Phase 2 | 20 | qynemeobee(ojkxpsgjtd) = none tbmhbhtmtz (xroeflgwme ) View more | Positive | 11 Dec 2023 | |||
NCT01373515 (Literature) Manual | Phase 1 | 12 | (Responder) | rfzbzygfkv(ndbeemhbpv) = kbmopdmslj iiwscufxqt (weqoiehjmo, 90–1849) View more | Positive | 02 Nov 2023 | |
(Non-responder) | rfzbzygfkv(ndbeemhbpv) = pggjnqlaek iiwscufxqt (weqoiehjmo ) View more | ||||||
Phase 2 | Acute Myeloid Leukemia Maintenance | 20 | bqptuzxqax(alqsnipolw) = vfhkvmdutg cifaeboupr (avgdjqvqso ) View more | Positive | 16 May 2022 | ||
Phase 1 | 12 | yhnoapkegf(uksgjamfbm) = jbxqsdlmqf zpagcxnbrv (tpeuhkyugy ) View more | Positive | 13 Nov 2019 |